Ascletis Pharma Inc. Announces Dosing of First Participants in U.S. Phase IIa Study of Oral GLP-1R Agonist ASC30 for Obesity Treatment

Reuters
07/03
<a href="https://laohu8.com/S/ASCLF">Ascletis Pharma Inc.</a> Announces Dosing of First Participants in U.S. Phase IIa Study of Oral GLP-1R Agonist ASC30 for Obesity Treatment

Ascletis Pharma Inc. has announced the commencement of a U.S. 13-week Phase IIa study involving participants with obesity or overweight, who have been dosed with the small molecule oral GLP-1 receptor agonist, ASC30. This investigational drug, designed for once-daily oral or once-monthly subcutaneous administration, demonstrated a placebo-adjusted mean body weight reduction of up to 6.5% from baseline after four weeks in a previous Phase Ib study. Topline data from the current Phase IIa study are expected to be presented in the fourth quarter of 2025. ASC30 is a new chemical entity with patent protection in the U.S. and globally until 2044.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 03, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10